Neuro-Medic Sp. z o.o. — Clinical Trial Site

24 Registered trials

8 Currently recruiting

Organisation

Neuro-Medic Sp. z o.o.

Location

Katowice, Poland

Identifier

ORG-100048220

Address

Ul. Zurawia 80, 40-686, Poland

Departments

#1711: Poradnia neurologiczna
4109
Chronic pain
N/A
NA
Neuro-Medic Poradnia Wielospecjalistyczna
Neuro-Medic Sp. z o.o. (#1)
Osrodek Badan Klinicznych Neuro-Medic Clinic
Poradnia Wielospecjalistyczna
unknown

Clinical trials at this site (24)

Search interface

A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P… Recruiting

2024-514617-35-00 Progressive forms of Multiple Sclerosis 4 2021-12-20
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting

2025-523757-33-00 multiple sclerosis 4 2026-05-07
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Relapsing multiple sclerosis 5 2025-06-18
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss Recruiting

2024-513835-25-00 Agitation with Dementia of the Alzheimer's Type 5 2022-10-27
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Upper limb spasticity after stroke or traumatic brain i 7 2021-04-29
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
RCT of Medical Cannabis Aerosol for DPNP Treatment Ended

2023-508932-68-00 Diabetic Peripheral Neuropathic Pain 4 2024-11-14
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Ended

2023-509555-13-00 Relapsing multiple sclerosis 1 2024-05-15
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514619-88-00 Relapsing Multiple Sclerosis 5 2022-03-18
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Ended

2024-516680-91-00 relapsing multiple sclerosis 5 2020-05-21
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
“A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended

2023-503289-22-00 Relapsing Multiple Sclerosis 4 2024-07-05
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant… Ended

2023-509078-45-00 Multiple sclerosis 4 2022-12-19
A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended

2024-514934-19-00 Post-surgical neuropathic pain 5 2021-11-08
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended

2024-514495-41-00 Primary Progressive Multiple Sclerosis 5 2020-11-04